Breaking News
'Its The Economy, Stupid!' Black And Hispanic Voters Embrace Trump On Economics And Well-Bei
We Need To Do With the State What We'Ve Done With Slavery
Is the 'Housing Shortage' the Result of Housing-Hoarding by the Wealthy?
The Dark Origins of the Davos' Great Reset
Top Tech News
Blazing bits transmitted 4.5 million times faster than broadband
Rewiring
Scientists Close To Controlling All Genetic Material On Earth
Doodle to reality: World's 1st nuclear fusion-powered electric propulsion drive
Phase-change concrete melts snow and ice without salt or shovels
You Won't Want To Miss THIS During The Total Solar Eclipse (3D Eclipse Timeline And Viewing Tips
China Room Temperature Superconductor Researcher Had Experiments to Refute Critics
5 video games we wanna smell, now that it's kinda possible with GameScent
Unpowered cargo gliders on tow ropes promise 65% cheaper air freight
Wyoming A Finalist For Factory To Build Portable Micro-Nuclear Plants
Prof Didier Raoult Releases the Results of a New Hydroxychloroquine Treatment Study on 1061 Patients
Professor Didier Raoult Releases the Results of a New Hydroxychloroquine Treatment Study on 1061 Patients
Posted on April 9, 2020
by covexit
The new study, of which the abstract was released today, was performed at IHU Méditerranée Infection, Marseille, France. A cohort of 1061 COVID-19 patients, treated for at least 3 days with the Hydroxychloroquine-Azithromycin (HCQ-AZ) combination and a follow-up of at least 9 days was investigated.
Key findings are:
•No cardiac toxicity was observed.
•A good clinical outcome and virological cure was obtained in 973 patients within 10 days (91.7%).
A poor outcome was observed for 46 patients (4.3%); 10 were transferred to intensive care units, 5 patients died (0.47%) (74-95 years old) and 31 required 10 days of hospitalization or more.
The authors conclude that:
"The HCQ-AZ combination, when started immediately after diagnosis, is a safe and efficient treatment for COVID-19, with a mortality rate of 0.5%, in elderly patients. It avoids worsening and clears virus persistence and contagiosity in most cases."
See the complete abstract below.
The original abstract can be accessed here.
Also, the researchers made this table available.
It's not clear when the complete study will be made available.
ABSTRACT
Background
In a recent survey, most physicians worldwide considered that hydroxychloroquine (HCQ) and azithromycin (AZ) are the two most effective drugs among available molecules against COVID-19. Nevertheless, to date, one preliminary clinical trial only has demonstrated its efficacy on the viral load. Additionally, a clinical study including 80 patients was published, and in vitro efficiency of this association was demonstrated.